EGFR and non-small cell lung carcinoma: In non-small cell lung cancer (NSCLC), EGFR alterations act as oncogenic drivers, revolutionizing patient outcomes with the use of tyrosine kinase inhibitors (TKIs) targeting EGFR [10].